CEO Herriot Tabuteau was paid $10,283,492 in fiscal year 2025, ↓ down 0.8% from fiscal year 2024, the 57th percentile of its disclosed peer group (SEC filing 0001193125-26-177610 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,283,492 ↓ Herriot Tabuteau total, FY2025 | 57th CEO pay percentile vs peers | 23:1 CEO-to-median pay ratio | 97.06% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AXSM's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Herriot Tabuteau | $835,000 | $0 | $5,533,554 | $2,833,237 | $876,750 | $0 | $204,951 | $10,283,492 |
| Chief Executive Officer, President, and Chairman of the Board | ||||||||
| Mark Jacobson | 575,000 | 0 | 2,082,943 | 1,066,620 | 388,000 | 0 | 95,568 | 4,208,131 |
| Chief Operating Officer | ||||||||
| Nick Pizzie | 530,000 | 0 | 1,822,596 | 933,329 | 358,000 | 0 | 86,594 | 3,730,519 |
| Chief Financial Officer | ||||||||
| Hunter Murdock | 530,000 | 0 | 1,497,075 | 766,593 | 358,000 | 0 | 72,636 | 3,224,304 |
| General Counsel | ||||||||
| Ari Maizel | 530,000 | 0 | 1,497,075 | 766,593 | 358,000 | 0 | 36,989 | 3,188,657 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Herriot Tabuteau | $10,283,492 | $10,364,688 | $9,896,629 | ↓ −81,196 |
| Mark Jacobson | 4,208,131 | 4,245,813 | 4,036,250 | ↓ −37,682 |
| Nick Pizzie | 3,730,519 | 3,756,389 | 3,565,817 | ↓ −25,870 |
| Hunter Murdock | 3,224,304 | 3,245,542 | 3,057,530 | ↓ −21,238 |
| Ari Maizel | 3,188,657 | 3,198,507 | 3,920,771 | ↓ −9,850 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Axsome Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AXSM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name AXSM as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Mark Coleman | Lead Independent Director | $514,745 |
| Mark Saad | Independent Director | $488,107 |
| Roger Jeffs | Independent Director | $482,362 |
| Susan Mahony | Independent Director | $476,470 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | D | 4,517 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | D | 4,517 | 228 | 1,029,605 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | A | 4,517 | 13 | 58,495 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-05 | — | 233 | — | — | 1 insider, 1 accrual row | ||
| Mark Jacobson | Chief Operating Officer | 2026-05-05 | D | 233 | 228 | 53,166 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-05 | A | 233 | 13 | 3,017 | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-05-29 | D | 6,000 | 233 | 1,400,760 | Common, open-market sale | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-01 | D | 6,000 | 230 | 1,381,800 | Common, open-market sale | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-02 | D | 5,537 | 223 | 1,236,910 | Common, open-market sale | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-05 | — | 6,884 | — | — | 4 insiders, 4 accrual rows | ||
| Dividend-equivalent accruals | 2026-06-08 | — | 5,716 | — | — | 4 insiders, 4 accrual rows | ||
| Mark Saad | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | D | 49,670 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | D | 33,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | D | 33,000 | 240 | 7,922,970 | Common, open-market sale | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | A | 33,000 | 4 | 115,500 | Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-09 | D | 300 | 237 | 71,163 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | D | 49,670 | 241 | 11,970,967 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | A | 49,670 | 5 | 245,867 | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-10 | D | 643 | 249 | 160,107 | Common, open-market sale | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-10 | D | 300 | 246 | 73,854 | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-10 | D | 286 | 246 | 70,407 | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-11 | D | 286 | 249 | 71,248 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | D | 49,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | D | 49,666 | 240 | 11,932,257 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | A | 49,666 | 5 | 245,847 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | D | 45,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | D | 45,004 | 212 | 9,541,298 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | A | 45,004 | 5 | 222,770 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | D | 4,660 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | D | 4,660 | 214 | 997,007 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | A | 4,660 | 5 | 23,067 | Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | D | 10,000 | 209 | 2,086,500 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | A | 10,000 | 13 | 129,500 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | D | 4,517 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | D | 4,517 | 228 | 1,029,605 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-04 | A | 4,517 | 13 | 58,495 | Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-05 | D | 233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-05 | D | 233 | 228 | 53,166 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-05-05 | A | 233 | 13 | 3,017 | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-05-29 | D | 6,000 | 233 | 1,400,760 | Common, open-market sale | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-01 | D | 6,000 | 230 | 1,381,800 | Common, open-market sale | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-02 | D | 5,537 | 223 | 1,236,910 | Common, open-market sale | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-05 | A | 1,721 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Saad | Director | 2026-06-05 | A | 1,721 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-05 | A | 1,721 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-05 | A | 1,721 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-08 | D | 1,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-08 | D | 1,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Saad | Director | 2026-06-08 | D | 1,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Saad | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-08 | D | 1,429 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-08 | A | 1,429 | — | — | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | D | 49,670 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | D | 33,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | D | 33,000 | 240 | 7,922,970 | Common, open-market sale | Form 4 ↗ |
| Nick Pizzie | Chief Financial Officer | 2026-06-09 | A | 33,000 | 4 | 115,500 | Common | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-09 | D | 300 | 237 | 71,163 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | D | 49,670 | 241 | 11,970,967 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-06-09 | A | 49,670 | 5 | 245,867 | Common | Form 4 ↗ |
| Mark Coleman | Director | 2026-06-10 | D | 643 | 249 | 160,107 | Common, open-market sale | Form 4 ↗ |
| Susan Mahony | Director | 2026-06-10 | D | 300 | 246 | 73,854 | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-10 | D | 286 | 246 | 70,407 | Common | Form 4 ↗ |
| Roger Jeffs | Director | 2026-06-11 | D | 286 | 249 | 71,248 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | D | 49,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | D | 49,666 | 240 | 11,932,257 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-07-01 | A | 49,666 | 5 | 245,847 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | D | 45,004 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | D | 45,004 | 212 | 9,541,298 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-05 | A | 45,004 | 5 | 222,770 | Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | D | 4,660 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | D | 4,660 | 214 | 997,007 | Common, open-market sale | Form 4 ↗ |
| Herriot Tabuteau | Director | 2026-08-06 | A | 4,660 | 5 | 23,067 | Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | D | 10,000 | 209 | 2,086,500 | Common, open-market sale | Form 4 ↗ |
| Mark Jacobson | Chief Operating Officer | 2026-09-03 | A | 10,000 | 13 | 129,500 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mark Jacobson | OPTION | 2025-02-21 | — | — | 10,875 | — | $1,066,620 |
| Herriot Tabuteau | OPTION | 2025-02-21 | — | — | 28,887 | — | 2,833,237 |
| Herriot Tabuteau | RSU | 2025-02-21 | — | — | 28,609 | — | 2,833,151 |
| Mark Jacobson | PSU | 2025-02-24 | 5,385 | 10,769 | — | 21,538 | 1,016,486 |
| Herriot Tabuteau | PSU | 2025-02-24 | 14,305 | 28,609 | — | 57,218 | 2,700,404 |
| Nick Pizzie | OPTION | 2025-02-21 | — | — | 9,516 | — | 933,329 |
| Nick Pizzie | PSU | 2025-02-24 | 4,712 | 9,423 | — | 18,846 | 889,437 |
| Ari Maizel | PSU | 2025-02-24 | 3,870 | 7,740 | — | 15,480 | 730,579 |
| Ari Maizel | RSU | 2025-02-21 | — | — | 7,740 | — | 766,496 |
| Nick Pizzie | RSU | 2025-02-21 | — | — | 9,423 | — | 933,159 |
| Hunter Murdock | RSU | 2025-02-21 | — | — | 7,740 | — | 766,496 |
| Mark Jacobson | RSU | 2025-02-21 | — | — | 10,769 | — | 1,066,457 |
| Ari Maizel | OPTION | 2025-02-21 | — | — | 7,816 | — | 766,593 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mark Jacobson | $1,066,457 | $1,016,486 | $1,066,620 | 32.3% |
| Herriot Tabuteau | 2,833,151 | 2,700,404 | 2,833,237 | 32.3% |
| Nick Pizzie | 933,159 | 889,437 | 933,329 | 32.3% |
| Ari Maizel | 766,496 | 730,579 | 766,593 | 32.3% |
| Hunter Murdock | 766,496 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Nick Pizzie | Option | 16,156 | 84 | — |
| Nick Pizzie | RSU | 13,379 | — | 2,443,541 |
| Nick Pizzie | RSU | 265,000 | — | 48,399,596 |
| Herriot Tabuteau | RSU | 35,540 | — | 6,491,026 |
| Herriot Tabuteau | RSU | 31,200 | — | 5,698,368 |
| Ari Maizel | RSU | 9,616 | — | 1,756,266 |
| Herriot Tabuteau | RSU | 28,609 | — | 5,225,148 |
| Herriot Tabuteau | PSU | 28,609 | — | 5,225,148 |
| Herriot Tabuteau | RSU | 27,715 | — | 5,061,868 |
| Nick Pizzie | RSU | 11,997 | — | 2,191,132 |
| Nick Pizzie | RSU | 11,745 | — | 2,145,107 |
| Nick Pizzie | RSU | 10,294 | — | 1,880,096 |
| Nick Pizzie | RSU | 11,707 | — | 2,138,166 |
| Ari Maizel | RSU | 10,868 | — | 1,984,932 |
| Nick Pizzie | RSU | 10,769 | — | 1,966,850 |
| Nick Pizzie | PSU | 10,769 | — | 1,966,850 |
| Nick Pizzie | RSU | 10,277 | — | 1,876,991 |
| Nick Pizzie | Option | 8,835 | 137.75 | — |
| Hunter Murdock | RSU | 9,616 | — | 1,756,266 |
| Nick Pizzie | RSU | 9,423 | — | 1,721,017 |
| Nick Pizzie | PSU | 9,423 | — | 1,721,017 |
| Hunter Murdock | RSU | 8,441 | — | 1,541,664 |
| Hunter Murdock | RSU | 7,740 | — | 1,413,634 |
| Nick Pizzie | Option | 12,945 | 65.32 | — |
| Hunter Murdock | PSU | 7,740 | — | 1,413,634 |
| Ari Maizel | RSU | 7,740 | — | 1,413,634 |
| Ari Maizel | PSU | 7,740 | — | 1,413,634 |
| Hunter Murdock | RSU | 6,924 | — | 1,264,599 |
| Nick Pizzie | Option | 11,326 | 65.32 | — |
| Herriot Tabuteau | Option | 13,103 | 29.91 | — |
| Herriot Tabuteau | Option | 34,385 | 65.32 | — |
| Herriot Tabuteau | Option | 49,045 | 84 | — |
| Nick Pizzie | Option | 5,587 | 29.91 | — |
| Hunter Murdock | Option | 6,350 | 137.75 | — |
| Herriot Tabuteau | Option | 23,470 | 137.75 | — |
| Nick Pizzie | Option | 4,867 | 29.91 | — |
| Nick Pizzie | Option | 7,731 | 137.75 | — |
| Nick Pizzie | Option | 18,464 | 84 | — |
| Hunter Murdock | Option | 3,273 | 29.91 | — |
| Hunter Murdock | Option | 9,304 | 65.32 | — |
| Hunter Murdock | Option | 13,271 | 84 | — |
| Ari Maizel | Option | 16,935 | 70.73 | — |
| Ari Maizel | Option | 13,271 | 84 | — |
| Ari Maizel | Option | 6,350 | 137.75 | — |
The company practices pay-for-performance, ensuring a significant percentage of NEO compensation is at-risk and tied to corporate and individual performance goals. They set challenging incentive plan goals for annual bonuses and PSUs, and align executive compensation with market practices by annually reviewing peer group companies.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-05 | 37,818,384 | 777,937 | 366,155 | 97.06% | Passed |
| 2025 | 2025-06-06 | 34,776,343 | 528,199 | 53,602 | 98.35% | Passed |
| 2024 | 2024-06-07 | 32,850,943 | 866,046 | 67,348 | 97.24% | Passed |
| 2023 | 2023-06-02 | 26,607,318 | 628,910 | 524,331 | 95.85% | Passed |
| 2022 | 2022-06-03 | 20,675,256 | 502,810 | 164,381 | 96.87% | Passed |
| 2021 | 2021-06-04 | 23,304,240 | 566,943 | 480,225 | 95.7% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-05 | 97.06%a |
| 2025 | 2025-06-06 | 98.35%b |
| 2024 | 2024-06-07 | 97.24%c |
a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal and broker non-votes will have no effect on the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $10,283,492 |
| Median employee compensation | $437,980 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark ColemanIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance · Audit | $114,834 | $159,919 | $239,992 | $0 | $0 | $514,745 |
| Mark SaadIndependent · Compensation · Nominating and Corporate Governance · Audit (Chair) | 88,196 | 159,919 | 239,992 | 0 | 0 | 488,107 |
| Roger JeffsIndependent · Compensation · Nominating and Corporate Governance (Chair) · Audit | 82,451 | 159,919 | 239,992 | 0 | 0 | 482,362 |
| Susan MahonyIndependent · Compensation (Chair) · Audit | 76,559 | 159,919 | 239,992 | 0 | 0 | 476,470 |
| Herriot TabuteauEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $362,040 |
| Equity awards (grant-date value) | $639,676 |
| All other compensation | $0 |
| Total cost of the board | $1,001,716 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Axsome Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Axsome Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | $1,044,000 | $10,606,275 | $1,874,992 | $0 | $14,944,585 |
| 2 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 3 | Zai Lab Limited | 2025 | Samantha Du | 908,730 | 3,233,729 | 5,822,084 | 695,178 | 10,677,221 |
| 4 | Axsome Therapeutics | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 5 | Revance Therapeutics, Inc | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 6 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 7 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 8 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Axsome Therapeutics | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Revance Therapeutics, Inc | 96.8% | PSU 100 | No | FW Cook |
| Zai Lab Limited | 85% | Options 65 · RSU 20 · PSU 15 | No | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Herriot Tabuteau | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Summary Compensation Table” · page 32. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 2 | Section 01, Mark Jacobson | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Summary Compensation Table” · page 32. As printed: 4,208,131. Filing ↗machine: t51 · r8 · c27 · span 961392–961401 |
| 3 | Section 01, Nick Pizzie | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Summary Compensation Table” · page 32. As printed: 3,730,519. Filing ↗machine: t51 · r5 · c27 · span 930748–930757 |
| 4 | Section 01, Hunter Murdock | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Summary Compensation Table” · page 32. As printed: 3,224,304. Filing ↗machine: t51 · r11 · c27 · span 992037–992046 |
| 5 | Section 01, Ari Maizel | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Summary Compensation Table” · page 32. As printed: 3,188,657. Filing ↗machine: t51 · r14 · c27 · span 1022662–1022671 |
| 6 | Section 03, Mark Jacobson OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c5 · span 823568–823574 |
| 7 | Section 03, Herriot Tabuteau OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c5 · span 796851–796857 |
| 8 | Section 03, Herriot Tabuteau RSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c9 · span 798226–798232 |
| 9 | Section 03, Mark Jacobson PSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c9 · span 824943–824949 |
| 10 | Section 03, Herriot Tabuteau PSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r2 · c9 · span 798226–798232 |
| 11 | Section 03, Nick Pizzie OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c5 · span 810216–810221 |
| 12 | Section 03, Nick Pizzie PSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c9 · span 811590–811595 |
| 13 | Section 03, Ari Maizel PSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 14 | Section 03, Ari Maizel RSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1351467–1351474 |
| 15 | Section 03, Nick Pizzie RSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r4 · c9 · span 811590–811595 |
| 16 | Section 03, Hunter Murdock RSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r8 · c9 · span 838300–838305 |
| 17 | Section 03, Mark Jacobson RSU | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t50 · r6 · c9 · span 824943–824949 |
| 18 | Section 03, Ari Maizel OPTION | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: span 1366840–1366847 |
| 19 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗ |
| 20 | Section 08, Mark Coleman | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Director Compensation”. As printed: 514,745. Filing ↗machine: span 578239–578447 |
| 21 | Section 08, Mark Saad | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Director Compensation”. As printed: 488,107. Filing ↗machine: span 596590–596798 |
| 22 | Section 08, Roger Jeffs | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Director Compensation”. As printed: 482,362. Filing ↗machine: span 584356–584564 |
| 23 | Section 08, Susan Mahony | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Director Compensation”. As printed: 476,470. Filing ↗machine: span 590482–590690 |
| 24 | Section 08, Herriot Tabuteau | DEF 14A | 2026-04-24 | 0001193125-26-177610 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 02, Mark Jacobson 2026-05-04 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Mark Jacobson 2026-05-04 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Mark Jacobson 2026-05-04 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Mark Jacobson 2026-05-05 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Mark Jacobson 2026-05-05 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Mark Jacobson 2026-05-05 | Form 4 | 2026-05-05 | 0001193125-26-207148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Mark Coleman 2026-05-29 | Form 4 | 2026-06-02 | 0001193125-26-254038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Mark Coleman 2026-06-01 | Form 4 | 2026-06-02 | 0001193125-26-254038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Mark Coleman 2026-06-02 | Form 4 | 2026-06-02 | 0001193125-26-254038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Roger Jeffs 2026-06-05 | Form 4 | 2026-06-09 | 0001193125-26-264030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Mark Saad 2026-06-05 | Form 4 | 2026-06-09 | 0001193125-26-264034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mark Coleman 2026-06-05 | Form 4 | 2026-06-09 | 0001193125-26-264041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Susan Mahony 2026-06-05 | Form 4 | 2026-06-09 | 0001193125-26-264040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mark Coleman 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266433 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Susan Mahony 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266435 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mark Saad 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266436 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Mark Saad 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266436 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Roger Jeffs 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266437 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Roger Jeffs 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266437 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Mark Coleman 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266433 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Susan Mahony 2026-06-08 | Form 4 | 2026-06-10 | 0001193125-26-266435 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Herriot Tabuteau 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Nick Pizzie 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Nick Pizzie 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Nick Pizzie 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Susan Mahony 2026-06-09 | Form 4 | 2026-06-10 | 0001193125-26-266435 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Herriot Tabuteau 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Herriot Tabuteau 2026-06-09 | Form 4 | 2026-06-09 | 0001193125-26-264038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Mark Coleman 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266433 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Susan Mahony 2026-06-10 | Form 4 | 2026-06-10 | 0001193125-26-266435 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Roger Jeffs 2026-06-10 | Form 4 | 2026-06-11 | 0001193125-26-268202 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Roger Jeffs 2026-06-11 | Form 4 | 2026-06-11 | 0001193125-26-268202 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Herriot Tabuteau 2026-07-01 | Form 4 | 2026-07-01 | 0001193125-26-292985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Herriot Tabuteau 2026-07-01 | Form 4 | 2026-07-01 | 0001193125-26-292985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Herriot Tabuteau 2026-07-01 | Form 4 | 2026-07-01 | 0001193125-26-292985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Herriot Tabuteau 2026-08-05 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Herriot Tabuteau 2026-08-05 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Herriot Tabuteau 2026-08-05 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Herriot Tabuteau 2026-08-06 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Herriot Tabuteau 2026-08-06 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Herriot Tabuteau 2026-08-06 | Form 4 | 2026-08-07 | 0001193125-26-340688 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Mark Jacobson 2026-09-03 | Form 4 | 2026-09-03 | 0001193125-26-382277 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Mark Jacobson 2026-09-03 | Form 4 | 2026-09-03 | 0001193125-26-382277 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Mark Jacobson 2026-09-03 | Form 4 | 2026-09-03 | 0001193125-26-382277 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 06, 2026 vote | Form 8-K | 2026-06-09 | 0001193125-26-264043 | Item 5.07 · say-on-pay result. As reported: 97.06% (votes for as printed: 37,818,384). Filing ↗ |
| 70 | Section 06, 2025 vote | Form 8-K | 2025-06-09 | 0000950170-25-083793 | Item 5.07 · say-on-pay result. As reported: 98.35% (votes for as printed: 34,776,343). Filing ↗ |
| 71 | Section 06, 2024 vote | Form 8-K | 2024-06-11 | 0000950170-24-071960 | Item 5.07 · say-on-pay result. As reported: 97.24% (votes for as printed: 32,850,943). Filing ↗ |
| 72 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 73 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 74 | Section 09b board cost (computed) | Computed | — | — | Cash 362,040 + equity 639,676 + all other 0 = 1,001,716, summed across the director compensation table rows.machine: formula: Σ = 1,001,716 |
| 75 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 76 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 77 | Zai Lab Limited, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001704292-26-000030 | CEO total compensation as printed in Zai Lab Limited's own proxy. As printed: 10,677,221. Filing ↗machine: span 553414–553424 |
| 78 | Axsome Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 79 | Revance Therapeutics, Inc, Section 10b CEO total | DEF 14A | 2024-03-21 | 0001479290-24-000071 | CEO total compensation as printed in Revance Therapeutics, Inc's own proxy. As printed: 10,068,915. Filing ↗machine: span 884809–884819 |
| 80 | Allogene Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 81 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 82 | Collegium Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 83 | Section 10a, Revance Therapeutics, Inc reciprocity | DEF 14A | — | 0001479290-24-000071 | Revance Therapeutics, Inc's most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
| 84 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc. names Axsome Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
| 86 | Section 10a, Collegium Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
| 87 | Section 10a, Zai Lab Limited reciprocity | DEF 14A | — | 0001704292-26-000030 | Zai Lab Limited's most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
| 88 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
| 89 | Section 10a, Allogene Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Axsome Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.